Oramed Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Oramed Pharmaceuticals Inc cash flow-to-debt ratio. Oramed Pharmaceuticals Inc (ORMP) has a Cash Flow-to-Debt Ratio of -0.10x as of March 2026, meaning its operating cash flow of $-2.92 Million could theoretically repay 0% of its total liabilities ($30.57 Million) in one year. Check cash flow quality index of Oramed Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Oramed Pharmaceuticals Inc (2003–2025)
Cash flow-to-debt ratio of Oramed Pharmaceuticals Inc from 2003 to 2025. Historical debt coverage capacity for Oramed Pharmaceuticals Inc across 22 annual periods. Check how aggressively does Oramed Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Oramed Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2003–2025)
Oramed Pharmaceuticals Inc cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Oramed Pharmaceuticals Inc. For the full cash flow conversion analysis, see Oramed Pharmaceuticals Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.29x | $-9.14 Million | $31.12 Million | ▲ +65.3% |
| 2024 | -0.85x | $-8.41 Million | $9.93 Million | ▼ -374.4% |
| 2023 | -0.18x | $-10.29 Million | $57.66 Million | ▲ +93.5% |
| 2022 | -2.74x | $-28.70 Million | $10.49 Million | ▼ -48.4% |
| 2021 | -1.84x | $-21.18 Million | $11.48 Million | ▼ -74.3% |
| 2020 | -1.06x | $-12.44 Million | $11.75 Million | ▼ -24.9% |
| 2019 | -0.85x | $-12.94 Million | $15.27 Million | ▲ +5.8% |
| 2018 | -0.90x | $-14.66 Million | $16.29 Million | ▼ -200.6% |
| 2017 | -0.30x | $-5.83 Million | $19.47 Million | ▼ -207.0% |
| 2016 | 0.28x | $4.66 Million | $16.64 Million | ▲ +108.6% |
| 2015 | -3.24x | $-4.95 Million | $1.53 Million | ▲ +19.6% |
| 2014 | -4.03x | $-4.07 Million | $1.01 Million | ▲ +37.1% |
| 2013 | -6.41x | $-3.40 Million | $529.41K | ▼ -322.7% |
| 2012 | -1.52x | $-2.30 Million | $1.52 Million | ▲ +45.2% |
| 2011 | -2.77x | $-1.67 Million | $602.02K | ▼ -21.1% |
| 2010 | -2.29x | $-1.42 Million | $620.62K | ▲ +47.7% |
| 2009 | -4.37x | $-2.25 Million | $515.66K | ▼ -117.4% |
| 2008 | -2.01x | $-1.84 Million | $913.95K | ▼ -368.4% |
| 2007 | -0.43x | $-611.00K | $1.42 Million | ▲ +27.7% |
| 2006 | -0.59x | $-361.61K | $608.91K | ▲ +32.3% |
| 2005 | -0.88x | $-40.44K | $46.07K | ▲ +78.1% |
| 2003 | -4.00x | $-40.00K | $10.00K | — |